Diversity and variability of the effects of nicotine on different cortical regions of the brain. Therapeutic and toxicological implications

Central Nervous System Agents in Medicinal Chemistry

Volumn 10, Issue 3, 2010, Pages 180-206

  Toledano, Adolfo ^a   Álvarez, María Isabel ^a   Toledano Díaz, Adolfo ^b  

^a INSTITUTO CAJAL   (Spain)

^b INIA   (Spain)

Author keywords

Brain cortex; Cyclooxygenase 2; Dehydrogenase hyperactivity; Hippocampus; NGF; Nicotine; Nicotine receptors; Nicotine toxic effects; Nicotinergic treatments; Nicotinic cholinergic systems; Oxidative stress

Indexed keywords

CYCLOOXYGENASE 2; LIPID PEROXIDE; NERVE GROWTH FACTOR; NICOTINE; NICOTINIC AGENT; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; ATTENTION DEFICIT DISORDER; BRAIN BLOOD FLOW; BRAIN CORTEX; BRAIN REGION; CITRIC ACID CYCLE; COGNITION; COGNITIVE DEFECT; DNA DAMAGE; DOSE RESPONSE; DRUG ACTIVITY; DRUG OVERDOSE; FRONTAL CORTEX; GLYCOLYSIS; HIPPOCAMPUS; HUMAN; LEARNING; LIPID PEROXIDATION; MEMORY; NERVE CELL PLASTICITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARIETAL LOBE; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 78649249224     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871524911006030180     Document Type: Article

References (232)

1. Gotti, C.; Moretti, M.; Gaimarri, A.; Zanardi, A.; Clementi F.; Zoli, M. Heterogeneity and complexity of native brain nicotinic receptors. Biochem. Pharmacol., 2007, 74, 1102-1111.
2. Taly, A.; Corringer, P.J.; Guedin, D.; Lestage, P.; Changeux, J.P. Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat. Rev. Drug Discov., 2009, 8, 733-750.
3. Collins, A.C.; Salminen O.; Marks, M.J.; Whiteaker, P.; Grady, S.R. The road to discovery of neuronal nicotinic cholinergic receptor subtypes. Handb. Exp. Pharmacol., 2009, 192, 85-112.
4. Toledano, A.; Alvarez, M.I.; Caballero, I.; Carmona, P.; De Miguel, E. Immunohistochemical increase in cyclooxygenase-2 without apoptosis in different brain areas of subchronic nicotine-and Damphetamine-treated rats. J. Neural. Transm., 2008, 115, 1093-1108.
5. Barik, J.; Wonnacott, S. Molecular and cellular mechanisms of action of nicotine in the CNS. Handb. Exp. Pharmacol., 2009, 192, 173-207.
6. Matta, S.G.; Balfour, D.J.; Benowitz, N.L.; Boyd, R.T.; Buccafusco, J.J.; Caggiula, A.R.; Craig, C.R.; Collins, A.C.; Damaj, M.I.; Donny, E.C.; Gardiner, P.S.; Grady, S.R.; Heberlein, U.; Leonard, S.S.; Levin, E.D.; Lukas, R.J.; Markou, A.; Marks, M.J.; McCallum, S.E.; Parameswaran, N.; Perkins, K.A.; Picciotto, M.R.; Quik, M.; Rose, J.E.; Rothenfluh, A.; Schafer, W.R.; Stolerman, I.P.; Tyndale, R.F.; Wehner, J.M.; Zirger, J.M. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl). 2007, 190, 269-319.
7. Levin, E. D. Nicotinic receptor subtypes and cognitive function. J. Neurobiol., 2002, 53, 633-640.
8. Levin, E.D.; McClernon, F.J.; Rezvani, A.H. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology, 2006, 184, 523-539.
9. Levin, E.D.; Rose, J.E. Acute and chronic nicotinic interactions with dopamine systems and working memory performance. Ann. N. Y. Acad. Sci., 1995, 757, 245-252.
10. Mansvelder, H.D.; Mertz, M.; Role, L.W. Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits. Semin. Cell Dev. Biol., 2009, 20, 432-440.
11. Paterson, N.E. The neuropharmacological substrates of nicotine reward: reinforcing versus reinforcement-enhancing effects of nicotine. Behav. Pharmacol., 2009, 20, 211-225.
12. Livingstone, P.D.; Wonnacott, S. Nicotinic acetylcholine receptors and the ascending dopamine pathways. Biochem. Pharmacol., 2009, 78, 744-755.
13. Shao, X.M.; Feldman, J.L. Central cholinergic regulation of respiration: nicotinic receptors. Acta Pharmacol. Sin., 2009, 30, 761-770.
14. Mudo, G.; Belluardo, N.; Fuxe, K. Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms. J. Neural. Transm., 2007, 114, 135-147.
15. Lester, H.A.; Xiao, C.; Srinivasan, R.; Son, C.D.; Miwa, J.; Pantoja, R.; Banghart, M.R.; Dougherty, D.A.; Goate, A.M.; Wang, J.C. Nicotine is a selective pharmacological chaperone of acetylcholine acetylcholine receptor number and stoichiometry. Implications for drug discovery. AAPS J., 2009, 11, 167-177.
16. López-Hernández, G.Y.; Thinschmidt, J.S.; Morain, P.; Trocme-Thibierge, C.; Kem, W.R.; Soti, F.; Papke, R.L. Positive modulation of alpha7 nAChR responses in rat hippocampal interneurons to full agonists and the alpha7-selective partial agonists, 4OH-GTS-21 and S 24795. Neuropharmacology, 2009, 56, 821-830.
17. Gu, R.X.; Gu, H.; Xie, Z.Y.; Wang, J.F.; Arias, H.R.; Wei, D.Q.; Chou, K.C. Possible drug candidates for Alzheimer's disease deduced from studying their binding interactions with alpha7 nicotinic acetylcholine receptor. Med. Chem., 2009, 5, 250-262.
18. Quik, M.; Huang, L.Z.; Parameswaran, N.; Bordia, T.; Campos, C.; Perez, X.A. Multiple roles for nicotine in Parkinson's disease. Biochem. Pharmacol., 2009, 78, 677-685.
19. Ward, R.J.; Lallemand, F.; de Witte, P.; Dexter, D.T. Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents. Prog. Neurobiol., 2008, 85, 135-147.
20. Wilens, T.E.; Decker, M.W. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem. Pharmacol., 2007, 74, 1212-1223.
21. Shimohama, S. Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models. Biol. Pharm. Bull., 2009, 32, 332-336.
22. Bartus, R.T.; Dean, R.L 3rd.; Beer, B.; Lippa, A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science, 1982, 217, 408-414.
23. Decker, M.W.; Rueter, L.E.; Bitner, R.S. Nicotinic acetylcholine receptor agonists: a potential new class of analgesics. Curr. Top. Med. Chem., 2004, 4, 369-384.
24. Vincler, M. Neuronal nicotinic receptors as targets for novel analgesics. Expert. Opin. Investig. Drugs, 2005, 14, 191-198.
25. Adams, J.D. Jr. Chemical interactions with pyramidal neurons in layer 5 of the cerebral cortex: control of pain and anxiety. Curr. Med. Chem., 2009, 16, 3476-3479.
26. Li, M.D.; Kane, J.K.; Konu, O. Nicotine, body weight and potential implications in the treatment of obesity. Curr. Top. Med. Chem., 2003, 3, 899-919.
27. Li M.D.; Kane, J.K. Effect of nicotine on the expression of leptin and forebrain leptin receptors in the rat. Brain Res., 2003, 991, 222-231.
28. Cooke, J. P.; Ghebremariam, Y. T. Endothelial nicotinic acetylcholine receptors and angiogenesis. Trends Cardiovasc. Med., 2008, 18, 247-253.
29. Martin, J.W.; Mousa, S.S.; Shaker, O.; Mousa, S.A. The multiple faces of nicotine and its implications in tissue and wound repair. Exp. Dermatol., 2009, 18, 497-505.
30. Ray, R.; Schnoll, R.A.; Lerman, C. Nicotine dependence: biology, behavior, and treatment. Annu. Rev. Med., 2009, 60, 247-260.
31. Penton, R.E.; Lester, R.A. Cellular events in nicotine addiction. Semin. Cell. Dev. Biol., 2009, 20, 418-431.
32. Benowitz, N.L. Pharmacology of nicotine: addiction, smokinginduced disease, and therapeutics. Annu. Rev. Pharmacol. Toxicol., 2009, 49, 57-71.
33. Chowdhury, P.; Udupa, K.B. Nicotine as a mitogenic stimulus for pancreatic acinar cell proliferation. World J. Gastroenterol., 2006, 12, 7428-7432.
34. Egleton, R.D.; Brown, K.C.; Dasgupta, P. Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis. Trends. Pharmacol. Sci., 2008, 29, 151-158.
35. Egleton, R.D.; Brown, K.C.; Dasgupta, P. Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases. Pharmacol. Ther., 2009, 121, 205-223.
36. Thunnissen, F.B. Acetylcholine receptor pathway and lung cancer. J. Thorac. Oncol., 2009, 4, 943-946.
37. Cooke, J.P. Angiogenesis and the role of the endothelial nicotinic acetylcholine receptor. Life Sci., 2007, 80, 2347-2351.
38. Arias, H.R.; Richards, V.E.; Ng, D.; Ghafoori, M.E.; Le, V.; Mousa, S.A. Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. Int. J. Biochem. Cell Biol., 2009, 41, 1441-1451.
39. Mariggio, M.A.; Guida, L.; Laforgia, A.; Santacroce, R.; Curci, E.; Montemurro, P.; Fumarulo, R. Nicotine effects on polymorphonuclear cell apoptosis and lipopolysaccharide-induced manocyte functions. A possible role in peridontal disease?. J. Peridontal. Res., 2001, 36, 32-39.
40. Demiralay, R.; Gursan, N.; Erdem, H. The effects of erdosteine, Nacetylcysteine, and vitamin E on nicotina-induced apoptosis of pulmonary cells. Toxicology, 2006, 219, 197-207.
41. Zeidler, R.; Albermann, K.; Lang, S. Nicotine and apoptosis. Apoptosis, 2007, 12, 1927-1943.
42. Berger, F.; Gage, F.H.; Vijayaraghavan, S. Nicotinic recptorinduced apoptostic cell death of hippocampal progenitor cells. J. Neurosci., 1998, 18, 6871-6881.
43. Jang, M.H.; Shing, M.C.; Jung, S.B.; Lee, T.H.; Bahn G.H.; Kwon, Y.K.; Kim, E.H.; Kim, C.J. Alcohol and nicotine reduce cell proliferation and enhance apoptosis in dentate gyrus. Neuroreport, 2002, 13, 1509-1513.
44. Mechawar, N.; Saghatelyan, A.; Grailhe, R.; Scoriels, L.; Gheusi, G.; Gabellec, M. M.; Lledo, P. M.; Changeux, J. P. Nicotinic receptors regulate the survival of newborn neurons in the adult olfactory bulb. Proc. Natl. Acad. Sci. USA, 2004, 101, 9822-9826.
45. Zhao, Z.; Reece, E.A. Nicotine-induced embryonic malformations mediated by apoptosis from increasing intracellular calcium and oxidative stress. Birth Defects Res. B/Dev. Reprod. Toxicol., 2005, 74, 383-391.
46. Arredondo, J.; Hall, L.L.; Ndoye, A.; Nguyen, V.T.; Chernyvsky, A.I.; Vercovich, D.; Orr Urtreger, A.; Beaudet, A.L.; Grando, S.A. Central role of fibroblast alpha3 nicotinic acetylcholine receptor in mediating cutaneous effects of nicotine. Lab. Invest., 2003, 83, 207-225.
47. Crowley-Weber, C.L.; Dvorakoya, K.; Crowley, C.; Bernstein, H.; Bernstein, C.; Garewal, H.; Payne, C.M. Nicotine increases oxidative stress, activates NF-kappa B and GRP78, induces apoptosis and sensitizes cells to genotoxic/xenobiotic stresses by a multiple stress inducer, deoxycholate: relevance to colon cercinogenesis. Chem. Biol. Interact. 2003, 145, 53-66.
48. Barr, J.; Sharma, C.S.; Sarkar, S.; Wise, K.; Dong, L.; Periyakaruppan, A.; Ramesh, G.T. Nicotine induces oxidative stress and activates nuclear transcription factor kappa B in rat mesencephalic cells. Mol. Cell. Biochem., 2007, 297, 93-99.
49. Rezvani, K.; Teng, Y.; Shim, D.; De Biasi, M. Nicotina regulates Multiple synaptic proteins by inhibiting proteosomal activity. J. Neurosci., 2007, 27, 10508-10519.
50. Dunckley, T.; Lukas, R.J. Nicotinic modulation of gene expression in SH-SY5Y neuroblastoma cells. Brain. Res., 2006, 1116, 39-49.
51. Wang, P.; Liang, Z.; Zeng, J.; Li, W.; Sun, X.; Miao, Z.; Tang, K. Generation of tobacco lines with widely different reduction in nicotine levels via RNA silencing approaches. J. Biosci., 2008, 33, 77-84.
52. Arredondo, J.; Nguyen, V.T.; Chernyavsky; A.I.; Bercovich, D.; Orr-Urtreger, A.; Kummer, W.; Lips, K.; Vetter, D.E.; Grando, S.A. Central role of alpha7 nicotinic receptor in differentiation of the stratified squamous epithelium. J. Cell. Biol., 2002, 159, 325-336.
53. Arredondo, J.; Chernyavsky, A.I.; Marubio, L.M.; Beaudet, A.L.; Jolkovsky, D. L.; Pinkerton, K.E.; Grando, S.A. Receptor-mediated tobacco toxicity: regulation of gene expression through alpha3beta2 nicotinic receptor in oral epithelial cells. Am. J. Pathol., 2005, 166, 597-613.
54. Arredondo, J.; Chernyavsky, A.I.; Jolkovsky, D.L.; Pinkerton, K.E; Grando, S. A. Receptor-mediated tobacco toxicity: acceleration of sequential expression of alpha5 and alpha7 nicotinic receptor subunits in oral keratinocytes exposed to cigarette smoke. FASEB J., 2008, 22, 1356-1368.
55. Suzuki, J.; Bayna, E.; Dalle Molle, E.; Lew, W.Y. Nicotine inhibits cardiac apoptosis induced by lipopolysaccharide in rats. J. Am. Coll. Cardiol., 2003, 41, 482-488.
56. Kawashima, K.; Fujii, T. The lymphocytic cholinergic system and its contribution to the regulation of immune activity. Life Sci., 2003, 74, 675-696.
57. Wright, S.C.; Zhong, J.; Zheng, H.; Larrick, J.W. Nicotine inhibition of apoptosis suggests a role in tumor promotion. FASEB J., 1993, 7, 1045-1051.
58. Heusch, W. L.; Maneckjee, R. Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells. Carcinogenesis, 1998, 19, 551-556.
59. Sun, X.; Liu, Y.; Hu, G.; Wang, H. Protective effects of nicotine against glutamate-induced neurotoxicity in PC12 cells. Cell. Mol. Biol. Lett., 2004, 9, 409-422.
60. Dajas-Bailador, F.A.; Lima, P.A.; Wonnacott, S. The alpha7 nicotinic acetylcholine receptor subtype mediates nicotine protection against NMDA excitotoxicity in primary hippocampal cultures through a Ca(2+) dependent mechanism. Neuropharmacology, 2000, 39, 2799-2807.
61. Wang, J.; Kim, J.M.; Donovan, D.M.; Becker, K.G.; Li, M.D. Significant modulation of mitochondrial electron transport system by nicotine in various rat brain regions. Mitochondrion, 2009, 9, 186-195.
62. Pascual, M.M.; Pastor, V.; Bernabeu, R.O. Nicotine-conditioned place preference induced CREB phosphorylation and Fos expression in the adult rat brain. Psychopharmacology (Berl), 2009, 207, 57-71.
63. Kane, J.K; Konu, O.; Ma, J.Z.; Li, M.D. Nicotine coregulates multiple pathways involved in protein modification/degradation in rat brain. Brain Res. Mol. Brain Res., 2004, 132, 181-191.
64. Marrero, M.B.; Bencherif, M. Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-inflammation: central role for JAK2 activation of STAT3 and NF-kappaB. Brain Res., 2009, 1256, 1-7.
65. Gentry, C.L.; Lukas, R.J. Regulation of nicotinic acetylcholine receptor numbers and function by cronic nicotine exposure. Curr. Drug Targets CNS Neurol. Disord., 2002, 1, 359-385.
66. Giniatullin, R.; Nistri, A.; Yakel, J.L. Desensitization of nicotinic Ach receptors: shaping cholinergic signaling. Trends Neurosci., 2005, 28, 371-378.
67. Besson, M.; Granon, S.; Mameli-Engvall, M.; Cloëz-Tayarani, I.; Maubourguet, N.; Cormier, A.; Cazala, P.; David, V.; Changeux, J. P.; Faure, P. Long-term effects of chronic nicotine exposure on brain nicotinic receptors. Proc. Natl. Acad. Sci. USA, 2007, 104, 8155-8160.
68. Newman, M.B.; Arendash, G.W.; Shytle, R.D.; Bickford, P.C.; Tighe, T.; Sanberg, P.R. Nicotine's oxidative and antioxidant properties in CNS. Life Sci., 2002, 71, 2807-2820.
69. Carmona, P.; Rodríguez-Casado, A.; Alvarez, M. I.; de Miguel, E.; Toledano, A. FTIR microspectroscopic analysis of the effects of certain drugs on oxidative stress and brain protein structure. Biopolymers, 2008, 89, 548-554.
70. Kane, J.K.; Hwang, Y.; Konu, O.; Loughlin, S. E.; Leslie, F.M.; Li, M.D. Regulation of Homer and group I metabotropic glutamate receptors by nicotine. Eur. J. Neurosci., 2005, 21, 1145-1154.
71. Gourlay, S.G.; Benowitz, N.L. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin. Pharmacol. Ther., 1977, 62, 456-463.
72. Shoaib, M.; Schindler, C.W.; Goldberg, S.R. Nicotine selfadministration in rats: strain and nicotine pre-exposure effects on adquisition. Psychopharmacology, 1997, 127, 35-43.
73. Pietilä, K.; Ahtee, L. Chronic nicotine administration in the drinking water affects the striatal dopamine in mice. Pharmacol. Biochem. Behav., 2000, 66, 95-103.
74. Quick, M.; Paraneswaran, N.; McCallum, S.E.; Bordia, T.; Bao, S.; McCormack, A.; Kim, A.; Tyndale, R.F.; Langston, J.W.; Di Monte, D.A. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-terated primates. J. Neurochem., 2006, 98, 1866-1875.
75. Turegano, L.; Martínez-Rodríguez, R.; Álvarez, M.I.; Gragera, R.R.; Gómez de Segura, A.; De Miguel, E.; Toledano, A. Histochemical study of acute and chronic intraperitoneal nicotine effects on several glycolytic and Krebs cycle dehydrogenase activities in the frontoparietal cortex and subcortical Nuclei of the rat brain. J. Neucosci. Res., 2001, 64, 626-635.
76. Martínez-Rodríguez, R.; Toledano, A.; Alvarez, M. I.; Turégano, L.; Colman, O.; Rosés, P.; Gómez de Segura, I.; De Miguel, E. Chronic nicotine administration increases NGF-like immunoreactivity in frontoparietal cerebral cortex. J. Neurosci. Res., 2003, 73, 708-716.
77. Changuex, J.P.; Bertrand, D.; Corringer, P.J.; Dehaene, S.; Edelstein, S.; Léna, C.; Le Novère, N.; Marubio, L.; Picciotto, M.; Zoli, M. Brain nicotinic receptors: structure and regulation, role in learning and reinforcement. Brain Res. Brain Res. Rev., 1998, 26, 198-216.
78. Papke, R.L.; Dwoskin, L.P.; Crooks, P.A. The pharmacological activity of nicotine and nornicotine on nAChRs subtypes: relevance to nicotine dependence and drug discovery. J. Neurochem., 2007, 101, 160-167.
79. Kawashima, K.; Fujii, T. Basic and clinical aspects of non-neuronal acetylcholine: overview of non-neuronal cholinergic systems and their biological significance. J. Pharmacol. Sci., 2008, 106, 167-173.
80. Dani, J.A.; Bertrand, D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu. Rev. Pharmacol. Toxicol., 2007,47, 699-729.
81. Albuquerque, E.X.; Pereira, E.F.; Alkondon, M.; Rogers, S.W. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol. Rev., 2009, 89, 73-120.
82. Millar, N.S.; Gotti, C. Diversity of vertebrate nicotinic acetylcholine receptors. Neuropharmacology, 2009, 56, 237-246.
83. Gaimarri, A.; Moretti, M.; Riganti, L.; Zanardi, A.; Clementi, F.; Gotti C. Regulation of neuronal nicotinic receptor traffic and expression. Brain Res. Rev., 2007, 55, 134-143.
84. Lendvai, B.; Vizi, E.S. Nonsynaptic chemical transmission through nicotinic acetylcholine receptors. Physiol. Rev., 2008, 88, 333-349.
85. Zoli, M.; Léna, C.; Picciotto, M.R.; Changeux, J.P. Identification of four classes of brain nicotine receptors using β2 mutant mice. J. Neurosci., 1998, 18, 4461-4472.
86. Paterson, D.; Nordberg, A. Neuronal nicotinic receptors in the human brain. Progr. Neurobiol., 2000, 61, 75-111.
87. Gotti, C.; Clementi, F. Neuronal nicotinic receptors: from structure to pathology. Prog. Neurobiol., 2004, 74, 363-396.
88. Steinlein, O.K.; Bertrand, D. Neuronal nicotinic acetylcholine receptors: from the genetic analysis to neurological diseases. Biochem. Pharmacol., 2008, 76, 1175-1183.
89. Le Novère, N.; Corringer, P.J.; Changeux, J.P. The diversity of subunit composition in nAChRs: evolutionary origins.; physiologic and pharmacologic consequences. J. Neurobiol., 2002, 53, 447-456.
90. Fucile, S. Ca2+ permeability of nicotinic acetylcholine receptors. Cell Calcium, 2004, 35, 1-8.
91. Dajas-Bailador, F.; Wonnacott, S. Nicotinic acetylcholine receptors and the regulation of neuronal signalling. Trends. Pharmacol. Sci., 2004, 25, 317-324.
92. Gotti, C.; Zoli, M.; Clementi, F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol. Sci., 2006, 27, 482-491.
93. Moroni, M.; Zwart, R.; Sher, E.; Cassels, B.K.; Bermudez, I. Alpha4 beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry and sensitivity to long-term exposure to nicotine. Mol. Pharmacol., 2006, 70, 755-768.
94. Champtiaux, N.; Gotti, C.; Cordero-Erausquin, M.; David, D.J.; Przybylski, C.; Léna, C.; Clementi, F.; Moretti, M.; Rossi, F.M.; Le Novère, N.; McIntosh, J.M.; Gardier, A.M.; Changeux, J.P. Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J. Neurosci., 2003, 23, 7820-7829.
95. Wu, H.Q.; Rassoulpour, A.; Schwarcz, R. Kynurenic acid leads.; dopamine follows: a new case of volume transmission in the brain? J. Neural. Transm., 2007, 114, 33-41.
96. Zmarowski, A.; Wu, H.Q.; Brooks, J.M.; Potter, M.C.; Pellicciari, R.; Schwarcz, R.; Bruno, J.P. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. Eur. J. Neurosci., 2009, 29, 529-538.
97. Drago, J.; McColl, C.D.; Horne, M.K.; Finkelstein, D.I.; Ross, S.A. Neuronal nicotinic receptors: insights gained from gene knockout and knockin mutant mice. Cell. Mol. Life. Sci., 2003, 60, 1267-1280.
98. Carnevale, D.; De Simone, R.; Minghetti, L. Microglia-neuron interaction in inflammatory and degenerative diseases: role of cholinergic and noradrenergic systems. CNS Neurol. Disord. Drug Targets, 2007, 6, 3883-3897.
99. Perry, D.C.; Dávila-García, M.I.; Stockmeier, C.A.; Kellar, K.J. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J. Pharmacol. Exp. Ther., 1999, 289, 1545-1552.
100. Picciotto, M.R.; Addy, N.A.; Mineur, Y.S.; Brunzell, D.H. It is not either/or: activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog. Neurobiol., 2008, 84, 329-342.
101. Takada-Takatori, Y.; Kume, T.; Ohgi, Y.; Fujii, T.; Niidome, T.; Sugimoto, H.; Akaike, A. Mechanisms of α7-nicotinic receptor upregulation and sensitization to donepezil induced by chronic donepezil treatment. Eur. J. Pharmacol., 2008, 590, 150-156.
102. Walsh, H.; Govind, A. P.; Mastro, R.; Hoda, J.C.; Bertrand, D.; Vallejo, Y.; Green, W.N. Up-regulation of nicotinic receptors by nicotine varies with receptor subtype. J. Biol. Chem., 2008, 283, 6022-6032.
103. Marks, M.J.; Pauly, J.R.; Gross, S.D.; Deneris, E.S.; Hermans-Borgmeyer, I.; Heinemann, S.F.; Collins, A.C. Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment. J. Neurosci., 1992, 12, 2765-8274.
104. Parker, S.L.; Fu, Y.; McAllen, K.; Luo, J.; McIntosh, J.M.; Lindstrom, J.M.; Sharp, B.M. Up-regulation of brain nicotinic acetylcholine receptors in the rat during long-term self-administration of nicotine: disproportionate increase of the alpha6 subunit. Mol. Pharmacol., 2004, 65, 611-622.
105. Mugnaini, M.; Garzotti, M.; Sartori, I.; Pilla, M.; Repeto, P.; Heidbreder, C. A.; Tessari, M. Selective down-regulation of [125I] Y0-alpha-conotoxin MII binding in rat mesostriatal dopamine pathway following continuous infusion of nicotine. Neuroscience, 2006, 137, 565-572.
106. Millar, N.S.; Harkness, P.C. Assembly and trafficking of nicotinic acetylcholine receptors. Mol. Membr. Biol., 2008, 25, 279-292.
107. Peng, X.; Gerzanich, V.; Anand, R.; Wang, F.; Lindstrom, J. Chronic nicotine treatment up-regulates alpha3 and alpha7 acetylcholine receptor subtypes expressed by the human neuroblastoma cell line SH-SY5Y. Mol. Pharmacol., 1997, 51, 776-784.
108. Vallejo, Y.F.; Buisson, B.; Bertrand, D.; Green, W.N. Chronic nicotine exposure upregulates nicotinic receptors by a novel mechanism. J. Neurosci., 2005, 25, 5563-5572.
109. Darsow, T.; Booker, T.K.; Pina-Crespo, J.C.; Heinemann, S.F. Exocytic trafficking is required for nicotine-induced up-regulation of alpha 4 beta 2 nicotinic acetylcholine receptors. J. Biol. Chem., 2005, 280, 18311-18320.
110. Sallette, J.; Bohler, S.; Benoit, P.; Soudant, M.; Pons, S.; Le Novere, N.; Chageux, J.P.; Corringer, P.J. An extracellular protein microdomain controls up-regulation of neuronal nicotinic acetylcholine receptors by nicotina. J. Biol. Chem., 2004, 279, 18767-18775.
111. Neff, R.A. 3rd.; Gomez-Varela, D.; Fernandes, C.C.; Berg, D.K. Postsynaptic scaffolds for nicotinic receptors on neurons. Acta Pharmacol. Sin., 2009, 30, 694-701.
112. Buccafusco, J.J.; Beach, J.W.; Terry, A.V. Jr. Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J. Pharmacol. Exp. Ther., 2009, 328, 364-370.
113. Monzón-Mayor, M.; Álvarez, M.I.; Arbelo-Galvan, J.F.; Romero-Alemán, M. M.; Yanes, C.; Plaza, M.L.; Rodríguez, J.R.; Rodríguez J.J.; Toledano, A. Long-term evolution of local, proximal and remote astrocyte responses after diverse nucleus basalis lesioning (an experimental Alzheimer model). GFAP immunocytochemical study. Brain Res., 2000, 865, 245-258.
114. Zhou, F.M.; Wilson, C.J.; Dani, J.A. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J. Neurobiol., 2002, 53, 590-605.
115. Umbriaco, D.; Watkins, K.C.; Descarries, L.; Cozzari, C.; Hartman, B.K. Ultrastructural and morphometric features of the acetylcholine innervation in adult rat parietal cortex: an electron microscopic study in serial sections. J. Comp. Neurol., 1994, 348, 351-373.
116. Umbriaco, D.; Garcia, S.; Beaulieu, C.; Descarries, L. Relational features of acetylcholine.; noradrenaline.; serotonin and GABA axon terminals in the stratum radiatum of adult rat hippocampus (CA1). Hippocampus, 1995, 5, 605-620.
117. Descarries, L.; Gisiger, V.; Steriade, M. Diffuse transmission by acetylcholine in the CNS. Prog. Neurobiol., 1997, 53, 603-625.
118. Mechawar, N.; Watkins, K.C.; Descarries, L. Ultrastructural features of the acetylcholine innervation in the developing parietal cortex of rat. J. Comp. Neurol., 2002, 443, 250-258.
119. Aznavour, N.; Watkins, K.C.; Descarries, L. Postnatal development of the cholinergic innervation in the dorsal hippocampus of rat: Quantitative light and electron microscopic immunocytochemical study. J. Comp. Neurol., 2005, 486, 61-75.
120. Horch, H.L.; Sargent, P.B. Perisynaptic surface distribution of multiple classes of nicotinic acetylcholine receptors on neurons in the chicken ciliary ganglion. J. Neurosci., 1995, 15, 7778-7795.
121. Buisson, B.; Bertrand, D. Chronic exposure to nicotine upregulates the human (alpha)4((beta)2 nicotinic acetylcholine receptor function. J. Neurosci., 2001, 21, 1819-1829.
122. Fabian-Fine, R.; Skehel, P.; Errington, M.L.; Davies, H.A.; Sher, E.; Stewart, M. G.; Fine A. Ultrastructural distribution of the alpha7 nicotinic acetylcholine receptor subunit in rat hippocampus. J. Neurosci., 2001, 21, 7993-8003.
123. Frazier, C.J.; Rollins, Y.D.; Breese, C.R.; Leonard, S.; Freedman, R.; Dunwiddie, T.V. Acetylcholine activates an alphabungarotoxin-sensitive nicotinic current in rat hippocampal interneurons.; but not pyramidal cells. J. Neurosci., 1998, 18, 1187-1195.
124. Adams, C.E.; Stitzel, J.A.; Collins, A.C.; Freedman, R. Alpha7-nicotinic receptor expression and the anatomical organization of hippocampal interneurons. Brain Res., 2001, 922, 180-190.
125. Kawai, H.; Zago, W.; Berg, D.K. Nicotinic alpha 7 receptor clusters on hippocampal GAB Aergic neurons: regulation by synaptic activity and neurotrophins. J. Neurosci., 2001, 22, 7903-7912.
126. Wanaverbecq, N.; Semyanov, A.; Pavlov, I.; Walker, M.C.; Kullmann, D.M. Cholinergic axons modulate GAB Aergic signaling among hippocampal interneurons via postsynaptic alpha 7 nicotinic receptors. J. Neurosci., 2007, 27, 5683-5693.
127. Léna, C.; Changues, J.P. Role of Ca2+ ions in nicotinic facilitation of GABA release in Mouse thalamus. J. Neurosci., 1997, 17, 576-585.
128. Exley, R.; Cragg, S.J. Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. Br. J. Pharmacol., 2008, 153, S283-S297.
129. Castro, N.G.; Albuquerque, E.X. alpha-Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability. Biophys. J., 1995, 68, 516-524.
130. Soliakov, L.; Wonnacott, S. Voltage-sensitive Ca2+ channels involved in nicotinic receptor-mediated [3H]dopamine release from rat striatal synaptosomes. J. Neurochem., 1996, 67, 163-170.
131. Fayuk, D.; Yakel, J.L. Dendritic Ca2+ signalling due to activation of alpha 7-containing nicotinic acetylcholine receptors in rat hippocampal neurons. J. Physiol., 2007, 582, 597-611.
132. Grady, S.; Marks, M.J.; Wonnacott, S.; Collins, A.C. Characterization of nicotinic receptor-mediated [3H] dopamine release from synaptosomes prepared from mouse striatum. J. Neurochem., 1992, 59, 848-856.
133. Turner, T.J. Nicotine enhancement of dopamine release by a calcium-dependent increase in the size of the readily releasable pool of synaptic vesicles. J. Neurosci., 2004, 24, 11328-11336.
134. Pauly, J.R.; Charriez, C.M.; Guseva, M.V.; Scheff, S.W. Nicotinic receptor modulation for neuroprotection and enhancement of functional recovery following brain injury or disease. Ann. N. Y. Acad. Sci., 2004, 1035, 316-334.
135. Szász, B.K.; Mayer, A.; Zsilla, G.; Lendvai, B.; Vizi, E.S.; Kiss, J.P. Carrier-mediated release of monoamines induced by the nicotinic acetylcholine receptor agonist DMPP. Neuropharmacology, 2005, 49, 400-409.
136. Sershen, H.; Balla, A.; Lajtha, A.; Vizi, E.S. Characterization of nicotinic receptors involved in the release of noradrenaline from the hippocampus. Neuroscience, 1997, 77, 121-130.
137. Girod, R.; Barazangi, N.; McGehee, D.; Role, L.W. Facilitation of glutamatergic neurotransmission by presynaptic nicotinic acetylcholine receptors. Neuropharmacology, 2000, 39, 2715-2725.
138. Maggi, L.; Sher, E.; Cherubini, E. Regulation of GABA release by nicotinic acetylcholine receptors in the neonatal rat hippocampus. J. Physiol., 2001, 536, 89-100.
139. Mansvelder, H.D.; McGehee, D.S. Long-term potentiation of excitatory inputs to brain reward areas b nicotine. Neuron, 2000, 27, 349-357.
140. Hasselmo, M.E. The role of acetylcholine in learning and memory. Curr. Opin. Neurobiol., 2006, 16, 710-715.
141. Alkondon, M.; Pereira, E.F.; Eisenberg, H.M.; Albuquerque, E.X. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J. Neurosci., 2000, 20, 66-75.
142. Vernino, S.; Amador, M.; Luetje, C.W.; Patrick, J.; Dani, J.A. Calcium modulation and high calcium permeability of neuronal nicotinic acetylcholine receptors. Neuron, 1992, 8, 127-134.
143. Séguéla, P.; Wadiche, J.; Dineley-Miller, K.; Dani, J.A.; Patrick, J.W. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J. Neurosci., 1993, 13, 596-604.
144. Welsby, P.; Rowan, M.; Anwyl, R. Intracellular mechanisms underlying the nicotinic enhancement of LTP in the rat dentate gyrus. Eur. J. Neurosci., 2009, 29, 65-75.
145. Vizi, E.S.; Lendvai, B. Modulatory role of presynaptic nicotinic receptors in synaptic and non-synaptic chemical communication in the central nervous system. Brain Res. Brain Res. Rev., 1999, 30, 219-235.
146. Vizi, E.S. Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in the central nervous system. Pharmacol. Rev., 2000, 52, 63-89.
147. Vizi, E.S.; Kiss, J.P.; Lendvai, B. Nonsynaptic communication in the central nervous system. Neurochem. Int., 2004, 45, 443-451.
148. Szabo, S.I.; Zelles, T.; Lendvai, B. Intracellular Ca2+ dynamics of hippocampal interneurons following nicotinic acetylcholine receptor activation. Neurochem. Int., 2008, 52, 135-141.
149. Brunzell, D.H.; Russell, D.S.; Picciotto, M.R. In vivo nicotine treatment regulates mesocorticolimbic CREB and ERK signaling in C57Bl/6J mice. J. Neurochem., 2003, 84, 1431-1441.
150. Valjent, E.; Pagès, C.; Hervé, D.; Girault, J.A.; Caboche, J. Addictive and non-addictive drugs induce distinct and specific patterns of ERK activation in mouse brain. Eur. J. Neurosci., 2004, 19, 1826-1836.
151. Dajas-Bailador, F.A.; Soliakov, L.; Wonnacott, S. Nicotine activates the extracellular signal-regulated kinase 1/2 via the alpha7 nicotinic acetylcholine receptor and protein kinase A, in SH-SY5Y cells and hippocampal neurones. J. Neurochem., 2002, 80, 520-530.
152. Shaw, S.; Bencherif, M.; Marrero, M.B. Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against Abeta-(1-42) amyloid. J. Biol. Chem., 2002, 277, 44920-44924.
153. Takada-Takatori, Y.; Kume, T.; Sugimoto, M.; Katsuki, H.; Sugimoto, H.; Akaike, A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology, 2006, 51, 474-786.
154. Zhang, J.; Berg, D.K. Reversible inhibition of GABA -A receptors by alpha-7 containing nicotinic receptors on the vertebrate postsynaptic neurons. J. Physiol., 2007, 579, 753-763.
155. Charpantier, E.; Wiesner, A.; Huh, K.H.; Ogier, R.; Hoda, J.C.; Allaman, G.; Raggenbass, M.; Feuerbach, D.; Bertrand, D.; Fuhrer, C. Alpha7 neuronal nicotinic acetylcholine receptors are negatively regulated by tyrosine phosphorylation and Src-family kinases. J. Neurosci., 2005, 25, 9836-9849.
156. Cho, C.H.; Song, W.; Leitzell, K.; Teo, E.; Meleth, A.D.; Quick, M.W.; Lester, R.A. Rapad upregulation of alpha7 nicotinic acetylcholine receptors by tyrosine dephosphorylation. J. Neurosci., 2005, 25, 3712-3723.
157. Hwang, Y.Y.; Li, M.D. Proteins differentially expressed in response to nicotine in five rat brain regions: identification using a 2-DE/MS-based proteomics approach. Proteomics, 2006, 6, 3138-3153.
158. Ferrari, R.; Le Novère, N.; Picciotto, M.R.; Changeux, J.P.; Zoli, M. Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. Eur. J. Neurosci., 2002, 15, 1810-1818.
159. Wang, F.; Chen, H.; Steketee, J.D.; Sharp, B.M. Upregulation of ionotropic glutamate receptor subunits within specific mesocorticolimbic regions during chronic nicotine self-administration. Neuropsychopharmacology, 2007, 32, 103-109.
160. Marshall, D.L.; Redfern, P.H.; Wonnacott, S. Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J. Neurochem., 1997, 68, 1511-1519.
161. Matsubayashi, H.; Amano, T.; Amano, H.; Sasa, M. Excitation of rat striatal large neurons by dopamine and/or glutamate released from nerve terminals via presynaptic nicotinic receptor (A4beta2 type) stimulation. Jpn. J. Pharmacol., 2001, 86, 429-436.
162. Sharples, C.G.; Kaiser, S.; Soliakov, L.; Marks, M.J.; Collins, A.C.; Washburn, M.; Wright, E.; Spencer, J.A.; Gallagher, T.; Whiteaker, P.; Wonnacott, S. UB-165: a novel nicotinic agonist with subtype selectivity implicates the alpha4beta2* subtype in the modulation of dopamine release from rat striatal synaptosomes. J. Neurosci., 2000, 20, 2783-2791.
163. Barik, J.; Wonnacott, S. Indirect modulation by alpha7 nicotinic acetylcholine receptors of noradrenaline release in rat hippocampal slices: interaction with glutamate and GABA systems and effect of nicotine withdrawal. Mol. Pharmacol., 2006, 69, 618-628.
164. McKay, D.B.; Chang, C.; González-Cestari, T.F.; McKay, S.B.; El-Hajj, R. A.; Bryant, D.L.; Zhu, M.X.; Swaan, P.W.; Arason, K.M.; Pulipaka, A.B.; Orac, C.M.; Bergmeier, S.C. Analogs of methylly caconitine as novel noncompetitive inhibitors of nicotinic receptors: pharmacological characterization, computational modeling, and pharmacophore development. Mol. Pharmacol., 2007, 71, 1288-1297.
165. Nisell, M.; Nomikos, G.G.; Svensson, T.H. Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol. Toxicol., 1994, 75, 348-352.
166. Mansvelder, H.D.; De Rover, M.; McGehee, D.S.; Brussaard, A.B. Cholinergic modulation of dopaminergic reward areas: upstream and downstream targets of nicotine addiction. Eur. J. Pharmacol., 2003, 480, 117-123.
167. Mansvelder, H.D.; McGehee, D.S. Cellular and synaptic mechanisms of nicotine addiction. J. Neurobiol., 2002, 53, 606-617.
168. 125I]-α-bungarotoxin. J. Neurosci., 1985, 5, 1307-1315.
169. Schultz, D.W.; Loring, R. H.; Aizenman, E.; Zigmond, R. E. Autoradiographic localization of putative nicotinic receptors in the rat brain using 125I-neuronal bungarotoxin. J. Neurosci., 1991, 11, 287-297.
170. 3H]cytisine. Neuroscience, 1994, 62, 929-994.
171. 3H]epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. J. Pharmacol. Exp. Neurol., 1995, 275, 1030-1034.
172. 3H]-methyllycaconitine in the mouse brain. Eur. J. Neurosci., 1999, 11, 2689-2696.
173. 3H] epibatidine in vitro autoradiography. Neuroscience, 1998, 85, 1121-1133.
174. Domino, E.F.; Minoshima, S.; Guthrie, S.; Ohl, L.; Ni, L.; Koeppe, R.A.; Zubieta, J.K. Nicotine effects on regional cerebral blood flow in awake, resting tobacco smokers. Synapse, 2000, 38, 313-321.
175. Linert, W.; Bridge, M.H.; Huber, M.; Bjugstad, K.B.; Grossman, S.; Arendash, G.W. In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson and Alzheimer disease. Biophys. Acta, 1999, 1454, 143-152.
176. Túnez, I.; Drucker-Colín, R.; Montilla, P.; Peña, J.; Jimena, I.; Medina, F.J.; Tasset, I. Protective effect of nicotine on oxidative and cell damage in rats with depression induced by olfactory bulbectomy. Eur. J. Pharmacol., 2010, 627, 115-118.
177. Reddy, V. P.; Zhu, X.; Perry, G.; Smith, M. A. Oxidative stress in diabetes and Alzheimer's disease. J. Alzheimers. Dis., 2009, 16, 763-774.
178. Zawia, N.H.; Lahiri, D.K.; Cardozo-Pelaez, F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic. Biol. Med., 2009, 46, 1241-1249.
179. Yokoyama, H.; Kuroiwa, H.; Yano, R.; Araki. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol. Sci., 2008, 29, 293-301.
180. Barros, D.M.; Galhardi, F.G.; Ribas F.J.L.; Guterres, L.B.; Dickel, O.; Geracitano, L.A.; Izquierdo, I.; Monserrat, J.M. The benefits and drawbacks of nicotine exposure in the cortex and hippocampus of old rats. Neurotoxicology, 2007, 28, 562-568.
181. Hutamekalin, P.; Farkas, A.E.; Orbók, A.; Wilhelm, I.; Nagyoszi, P.; Veszelka, S.; Deli, M.A.; Buzás, K.; Hunyadi-Gulyás, E.; Medzihradszky, K. F.; Meksuriyen, D.; Krizbai, I.A. Effect of nicotine and polyaromtic hydrocarbons on cerebral endothelial cells. Cell. Biol. Int., 2008, 32, 198-209.
182. Arrick, D.M.; Mayhan, W.G. Acute infusion of nicotine impairs nNOS-dependent reactivity of cerebral arterioles via an increase in oxidative stress. J. Appl. Physiol., 2007, 103, 2062-2067.
183. Túnez, I.; Montilla, P.; Muñoz, M.C.; Drucker-Colín, R. Effect of nicotine on 3-nitropropionic acid-induced oxidative stress in synaptosomes. Eur. J. Pharmacol., 2004, 504, 169-175.
184. McIlwain, H. Biochemistry and the central nervous system. Churchill Ltd. London: 1966.
185. Uchida, S.; Kagitani, F.; Nakayama, H.; Sato, A. Effect of stimulation of nicotinic cholinergic receptors on cortical cerebral blood flow and changes in the effect during aging in anesthetized rats. Neurosci. Lett., 1997, 228, 203-206.
186. Uchida, S.; Hotta, H.; Kawashima, K. Long-term nicotine treatment reduces cerebral cortical vasodilation mediated by alpha4beta2-like nicotinic acetylcholine receptors in rats. Eur. J. Pharmacol., 2009, 609, 100-104.
187. Laughton, J.D.; Charnay, Y.; Belloir, B.; Pellerin, L.; Magistretti, P.J.; Bouras, C. Differential messenger RNA distribution of lactate dehydrogenase LDH-1 and LDH-5 isoforms in the rat brain. Neuroscience, 2000, 96, 619-625.
188. Kalaria, R.N.; Homayoun, P.; Whitehouse, P.J. Nicotinic cholinergic receptors associated with mammalian cerebral vessels. J. Auton. Nerv. Syst., 1994, 49, S3-S7.
189. Belluardo, N.; Olsson, P.A.; Mudo, G.; Sommer, W.H.; Amato, G.; Fuxe, K. Transcription factor gene expression profiling after acute intermittent nicotine treatment in the rat cerebral cortex. Neuroscience, 1995, 133, 787-796.
190. Gueorguiev, V.D.; Zeman, R.J.; Meyer, E.M.; Sabban, E.L. Involvement of alpha7 nicotinic acetylcholine receptors in activation of tyrosine hydroxylase and dopamine beta-hydroxylase gene expression in PC12 cells. J. Neurochem., 2000, 75, 1997-2005.
191. Jonnala, R.R.; Buccafusco, J.J. Relationship between the increased cell surface alpha7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists. J. Neurosci. Res., 2001, 66, 565-572.
192. Prendergast, M.A.; Buccafusco, J. (2)-Nicotine increases mRNA encoding G3PDH and the vesicular acetylcholine transporter in vivo. J. Neuroreport, 1998, 9, 1385-1389.
193. Sokoloff, L. The deoxyglucose method for the measurement of local glucose utilization and the mapping of local functional activity in the central nervous system. Int. Rev. Neurobiol., 1981, 25, 287-233.
194. Blin, J.; Ray, C.A.; Piercey, M.F.; Bartko, J.J.; Mouradian, M.M.; Chase, T. N. Comparison of cholinergic drug effects on regional brain glucose consumption in rats and humans by means of autoradiography and positron emission tomography. Brain Res., 1994, 635, 196-202.
195. Martínez-Rodríguez, R.; Martínez-Murillo, R. In vitro Damphetamine action on oxido-reductase activity in several rat nervous centers. Acta Histochem., 1984, 74, 85-90.
196. Martínez-Murillo, R.; Martínez-Rodríguez, R.; Arenas-Díaz, G. Succinic and malic dehydrogenase activities in cerebral.; cerebellar and neostriatum sections incubated in presence of D-amphetamine. Acta Neuropathol., 1985, 67, 81-85.
197. Nanri, M.; Kasahara, N.; Yamamoto, J.; Miyake, H.; Watanabe, H. GTS-21.; a nicotinic agonist.; protects against neocortical neuronal cell loss induced by the nucleus basalis magnocellularis lesion in rats. Jpn. J. Pharmacol., 1997, 74, 285-289.
198. Sanderson, E.M.; Drasdo, A.L.; McCrea, K.; Wonnacott, S. Upregulation of nicotinic receptors following continuous infusion of nicotine is brainregion-specific. Brain Res., 1993, 617, 349-352.
199. Pauly, J.R.; Marks, M.J.; Gross, S.D.; Collins, A.C. An autoradiographic analysis of cholinergic receptors in mouse brain after chronic nicotine treatment. J. Pharmacol. Exp. Ther., 1991, 258, 1127-1136.
200. Ma, W.; Hohmann, C.F.; Coyle, J.T.; Juliano, S.L. Lesions of the basal forebrain alter stimulus-evoked metabolic activity in mouse somatosensory cortex. J. Comp. Neurol., 1989, 288, 414-427.
201. Mattson, M.P.; Pederson, W.A.; Duan, W.; Culmsee, C.; Camandola, S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer disease. Ann. N. Y. Acad. Sci., 1999, 893, 154-175.
202. Fujii, S.; Ji, Z.; Morita, N.; Sumikawa, K. Acute and chronic nicotine exposure differentially facilitate the induction of LTP. Brain Res., 1999, 846, 137-143.
203. Ji, D.; Lape, R.; Dani, J.A. Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity. Neuron, 2001, 31, 131-141.
204. Welsby, P.J.; Rowan M.J.; Anwyl, R. Beta-amyloid blocks high frequency stimulation induced LTP but not nicotine enhanced LTP. Neuropharmacology, 2007, 53, 188-195.
205. Mann, E.O.; Greenfield, S.A. Novel modulatory mechanisms revealed by the sustained application of nicotine in the guinea-pig hippocampus in vitro. J. Physiol., 2003, 551, 539-550.
206. Couey, J.J.; Meredith, R.M.; Spijker, S.; Poorthuis, R.B.; Smit, A.B.; Brussaard, A.B.; Mansvelder, H.D. Distributed network actions by nicotine increase the threshold for spike-timing-dependent plasticity in prefrontal cortex. Neuron, 2007, 54, 73-87.
207. Rattray, M. Is there nicotinic modulation of nerve growth factor? Implications for cholinergic therapies in Alzheimer's disease. Biol. Psychiatry, 2001, 49, 185-193.
208. Sofroniew, M.V.; Howe, C.L.; Mobley, W.C. Nerve growth factor signaling neuroprotection and neuronal repair. Annu. Rev. Neurosci., 2001, 24, 1217-1281.
209. Knipper, M.; da Penha Berzaghi, M.; Blochl, A.; Breer, H.; Thoenen, H.; Lindholm, D. Positive feedback between acetylcholine and neurotrophins nerve growth factor and brain derived neurotrophic factor in the hippocampus. Eur. J. Neurosci., 1994, 4, 668-671.
210. Nonner, D.; Barrett, E.F.; Barrett, J.N. Brief exposure to neurotrophins produces a calcium-dependent increase in choline acetyltransferase activity in cultured rat septal neurons. J. Neurochem., 2000, 74, 268-278.
211. Olson, L.; Nordberg, A.; van Holst, H.; Backman, L.; Ebental, T.; Alafuzodf, I.; Amberla, K.; Hartvig, P.; Herlitz, A.; Lilja, A. Nerve growth factor affects 11C-nicotine binding.; blood flow.; EEG and verbal episodic memory in an Alzheimer patient. J. Neural. Transm., (Park Dement Section). 1992, 4, 79-95.
212. Kenny, P.J.; File, S.E.; Razttray, M. Acute nicotine decreases and chronic nicotine increases the expression of brain-derived neurotrophic factor mRNA in rat hippocampus. Mol. Brain Res., 2000, 85, 234-238.
213. Katoh-Semba, R.; Takeuchi, I.K.; Kato, K. Age-related changes in levels of brain-derived neurotrophic factor in selected brain regions of rats.; normal mice and senescence-accelerated mice: a comparison to those of nerve growth factor and neurotrophin-3. Neurosci. Res., 1998, 31, 227-234.
214. Toledano, A. Growth factors and aging factors in Alzheimer's disease. Selmes, S.; Selmes, J.; Portera, A.; Toledano, A.; Eds. Updating of Alzheimer's disease. Madrid: Fundación Alzheimer España/Alzheimer Europa/Meditor, 1994, pp: 59-71.
215. Hefti, F. Development of effective therapy for Alzheimer's disease based on neurotrophic factors. Neurobiol. Aging, 1994, 2, S193-S194.
216. Scott, S.A.; Crutcher, K.A. Nerve growth factor and Alzheimer's disease. Rev. Neurosci., 1994, 5, 179-211.
217. Siegel, G.J.; Chauhan, N.B. Neurotrophic factors in Alzhiemer's and Parkinson's disease brain. Brain Res. Rev., 2000, 33, 199-227.
218. Rossner, S.; Ueberham, U.; Schiliebs, R.; Perez-Polo, J.R.; Bigl, V. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog. Neurobiol., 1998, 56, 541-569.
219. Yamagata, K.; Andreasson, K.I.; Kaufmann, W.E.; Barnes, C.A.; Worley, P. F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron, 1993, 11, 371-386.
220. Breder, C.D.; Dewitt, D.; Kraig, R.P. Characterization of inducible cyclooxygenase in rat brain. J. Comp. Neurol., 1995, 355, 296-315.
221. Kaufman, W.E.; Andreasson, K.I.; Isakson, P.C.; Worley, P.F. Cyclooxygenases and the central nervous system. Prostaglandins, 1997, 54, 601-624.
222. Schiltz, J.C.; Sawchenko, P.E. Distinct brain vascular cell types manifest inducible cyclooxygenase expression as a function of the strength and nature of immune insults. J. Neurosci., 2002, 22, 5606-5618.
223. Choi, S.H.; Langenbach, R.; Bosetti, F. Cyclooxygenase-1 and -2 enzymes differentially regulate the brain upstream NF-kappa B pathway and downstream enzymes involved in prostaglandin biosynthesis. J. Neurochem., 2006, 98, 801-811.
224. Hoozemans, J.J.; Rozemuller, A.J.; Veerhuis, R.; Eikelenboom, P. Immunological aspects of Alzheimer's disease: therapeutic implications. BioDrugs, 2001, 15, 325-337.
225. Deininger, M.H.; Bekure-Nemariam, K.; Trautmann, K.; Morgalla, M.; Meyermann, R.; Schlucsener, H.J. Cyclooxygenase-1 and -2 in brains of patients who died with sporadic Creutzfeldt-Jakob disease. J. Mol. Neurosci., 2003, 20, 25-30.
226. Giovannini, M.G.; Scali, C.; Prosperi, C.; Bellucci, A.; Pepeu, G.; Casamenti, F. Experimental brain inflammation and neurodegenerations as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors. Int. J. Immunopathol. Pharmacol., 2003, 16, S31-S40.
227. Eikelenboom, P.; Van Gool, W.A. Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J. Neural. Transm., 2004, 111, 281-294.
228. Chang, Y.W.; Jakobi, R.; McGinty, A.; Foschi, M.; Dunn, M.J.; Sorokin, A. Cyclooxygenase 2 promotes cell survival by stimulation of dynein light chain expression and inhibition of neuronal nitric oxide synthase activity. Mol. Cell Biol., 2000, 20, 8571-8579.
229. Dash, P.K.; Mach, S.A.; Moore, A.N. Regional expression and role cyclooxygenase-2 following experimental traumatic brain injury. J. Neurotrauma, 2000, 17, 69-81.
230. Consilvio, C.; Vicent, A.M.; Feldman, E.L. Neuroinflammation.; COX-2.; and ALS. A dual role? Exp. Neurol., 2004, 187, 1-10.
231. Gahring, L.C.; Persiyanov, K.; Days, E.L.; Rogers, S.W. Agerelated loss of neuronal nicotinic receptor expression in the aging mouse hippocampus corresponds with cyclooxygenase-2 and PPAR gamma expression and is altered by long-term NS398 administration. J. Neurobiol., 2005, 62, 453-468.
232. Sharifzadeh, M.; Tavasoli, M.; Naghdi, N.; Ghanbari, A.; Amini, M.; Roghani, A. Post-training intrahippocampal infusion of nicotine prevents spatial memory retention deficits induced by the cyclo-oxygenase-2-specific inhibitor celecoxib in rats. J. Neurochem., 2005, 95, 1078-1090.